T-Cypher Bio
Nathaniel Davies has held various roles in computational biology and bioinformatics at companies such as T-Cypher Bio, Nucleome Therapeutics, and Immunocore. Nathaniel has experience in setting up computational biology teams, initiating drug development pipelines, and working on target discovery databases. Prior to their industry roles, Nathaniel conducted research on immune escape mechanisms of pancreatic cancer as a Postdoctoral Researcher at the University of Birmingham. Nathaniel holds a PhD in Genetics from the University of Leicester, a Master's degree in Computer Science & Artificial Intelligence from Loughborough University, and a Bachelor's degree in Computer Software Engineering from Derby College.
This person is not in any teams
T-Cypher Bio
T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies.T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.